ClinicalTrials.gg
Not yet recruitingNCT05911048Updated Jul 25, 2024

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

A Phase 2 interventional study of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) and Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101) in COVID-19, sponsored by WestVac Biopharma Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by WestVac Biopharma Co., Ltd. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. — 3 open to participants now, 3 under way, 2 of them phase 3. COVID-19 · WestVac Biopharma Co., Ltd..

Planned enrollment
4th of 11
3,100 · median 450
Started
2024
with 2 others
Phase 2
4 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., this one is the 4th largest by planned enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 8th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 11 studies in COVID-19 by WestVac Biopharma Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in COVID-19 by WestVac Biopharma Co., Ltd., or all of them as a file.
02

Study summary

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.

Read the detailed description

To evaluate safety of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) and immunogenicity superiority of WSK-V101C to Recombinant COVID-19 vaccine (WSK-V101) after booster.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18 years and above, including those with underlying diseases and subjects.
  2. Basic or booster immunization with COVID-19 vaccine ≥6 months.
  3. ≥3 months of SARS-CoV-2 infection history, or never infected.
  4. Have the ability to understand research procedures, with , voluntarily sign informed consent, and be able to comply with the requirements of clinical research protocols.

Exclusion criteria

Exclusion Criteria:

  1. Axillary temperature ≥37.3℃.
  2. SARS-CoV-2 antigen or nucleic acid screening positive within the last 48 hours.
  3. Anti-SARS-CoV-2 IgM antibody was positive during the screening period.
  4. It is in the advanced stage of malignant tumor and the disease control is unstable.
  5. Female pregnancy (pregnancy test results are positive), lactation period.
  6. Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, heart failure, severe hypertension, and can not be controlled by drugs.
  7. Have other serious chronic conditions such as uncontrolled asthma, diabetes, , pulmonary embolism, chronic kidney disease requiring dialysis, cirrhosis of the liver, convulsions, epilepsy and other neurological/psychiatric conditions.
  8. Have been diagnosed with congenital or acquired immunodeficiency, infection.
  9. People who are allergic to any component of the vaccine have a history of more severe allergies or allergic reactions to the vaccine in the past.
  10. Congenital or acquired angioedema/neuroedema.
  11. Asplenia or functional asplenia.
  12. Thrombocytopenia or other clotting disorders (which may cause intramuscular injection ).
  13. Received another investigational drug within 1 month prior to receiving the investigational vaccine.
  14. Received subunit or inactivated vaccine within 14 days prior to receiving the investigational vaccine, or received within 1 month.
  15. Fertile female subjects did not use effective within 1 month prior to enrollment.
  16. Fertile female and male subjects have pregnancy plans and sperm/egg donation plans from the screening period to 3 months after immunization.
  17. Abnormal laboratory test results during the screening period, which were judged by the researcher to be unsuitable for the study vaccine.
  18. Medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,100 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

    Biological: Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

  • Active comparator
    Control group

    Recombinant COVID-19 Vaccine (Sf9 Cell)(WSK-V101)

    Biological: Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)

Interventions

  • BiologicalRecombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

    boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)

  • BiologicalRecombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)

    boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)

06

What researchers measure

Primary outcomes

  1. AE and AR

    Incidence of adverse events (AE) and adverse reactions (AR) 0-7 days after vaccination.

    Time frame: 0-7 days after vaccination

  2. Primary Immunogenicity indicator

    The geometric mean titer (GMT) and seroconversion of neutralizing antibodies (true virus or pseudovirus method) against the current variants of SARS-CoV-2 (such as XBB and its subtypes) at day 14 post-vaccination.

    Time frame: day 14 post-vaccination

Secondary outcomes

  1. AE and AR

    Incidence of adverse events (AE) and adverse reactions (AR) 0-30 days post-vaccination.

    Time frame: 0-30 days post-vaccination.

  2. SAE and AE

    Incidence of serious adverse events (SAE) and adverse events of specific interest (AESI) within 12 months post-vaccination.

    Time frame: within12 months post-vaccination.

  3. Secondary Immunogenicity indicator 1

    Geometric mean titer (GMT) and seroconversion rate of neutralizing antibody (true virus or pseudovirus method) against SARS-CoV-2 prototype strain and Omicron BA.2 variant strain on day 14 post-vaccination.

    Time frame: day 14 post-vaccination.

  4. Secondary Immunogenicity indicator 2

    Geometric mean fold increase (GMI) of neutralizing antibodies against SARS-CoV-2 prototype strains, current variants (such as XBB and its subtypes), and Omicron BA.2 variants (true virus or pseudovirus method) on day 14 post-vaccination.

    Time frame: day 14 post-vaccination

  5. Secondary Immunogenicity indicator 3

    Geometric mean titer (GMT), seroconversion rate and geometric mean fold increase (GMI) against SARS-CoV-2 prototype strains, current variants (such as XBB and its subtypes) and Omicron BA.2 variants neutralizing antibodies (true virus or pseudovirus method) at day 30 post-vaccination.

    Time frame: day 30 post-vaccination.

  6. Secondary Immunogenicity indicator 4

    Geometric mean titer (GMT), seroconversion rate and geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific binding antibodies at 14 and 30 days after vaccination.

    Time frame: 14 and 30 days post-vaccination.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Jun 2025, 6 months later.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 6 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 20, 2023
StartEst.
Dec 30, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05911048
Lead sponsor
WestVac Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jun 20, 2023
Start date
Dec 30, 2024 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jul 25, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion